Rubius Therapeutics
Biotechnology, 399 Binney St Ste 300, Cambridge, Massachusetts, 02139, United States, 201-500 Employees
Phone Number: 61********
Who is RUBIUS THERAPEUTICS
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORMTM was designed to genetically engineer and culture Red Cell The...
Read More
-
Headquarters: 399 Binney St Ste 300, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 2014
-
Employees: 201-500
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from RUBIUS THERAPEUTICS
Rubius Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Rubius Therapeutics
Answer: Rubius Therapeutics's headquarters are located at 399 Binney St Ste 300, Cambridge, Massachusetts, 02139, United States
Answer: Rubius Therapeutics's phone number is 61********
Answer: Rubius Therapeutics's official website is https://rubiustx.com
Answer: Rubius Therapeutics's revenue is $1 Million to $5 Million
Answer: Rubius Therapeutics's SIC: 2836
Answer: Rubius Therapeutics's NAICS: 541714
Answer: Rubius Therapeutics has 201-500 employees
Answer: Rubius Therapeutics is in Biotechnology
Answer: Rubius Therapeutics contact info: Phone number: 61******** Website: https://rubiustx.com
Answer: Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORMTM was designed to genetically engineer and culture Red Cell TherapeuticsTM that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCTTM product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month